Veracyte Completes Enrollment for Clinical Utility Trial to Evaluate Nasal Swab Lung Cancer Test

Veracyte (VCYT) said Tuesday that it has reached its target enrollment for a clinical utility trial evaluating its Percepta Nasal Swab test.

The cancer diagnostics company said the trial has now enrolled 2,400 patients at more than 90 academic and community centers across the US.

The test is used to assess molecular changes associated with lung cancer risk in patients with lung nodules and a history of smoking, the company said.

Shares of Veracyte were up 6% in recent Tuesday premarket activity.